Skip to main content

Editorial [Hot Topic: Recent Strategies for Potentiation and Facilitation of Antidepressant Treatment (Guest Editor: Eliyahu Dremencov)]

Buy Article:

$55.00 plus tax (Refund Policy)

It was my great honor and pleasure to be suggested for the guest editing of the theme issue in Current Drug Targets and to prepare this issue entitled "Recent strategies for potentiation and facilitation of antidepressant treatment".

Major depression is a severe and dangerous mental disorder with a lifetime prevalence of 20%. Throughout over 50 years of research and drug development, different classes of medications were developed and showed efficacy in the treatment of major depression. However, the main limitations of most antidepressant drugs are a long delay between the beginning of treatment and the onset of the therapeutic effect of the treatment, a high percentage of patients do not respond to the treatment and a high risk of rapid relapse to depression even after effective treatment.

Therefore, understanding the mechanisms of action of antidepressant drugs and developing new strategies for potentiation and facilitation of the treatment of depression is one of the main targets of current psychopharmacological research. The aim of the issue was to summarize the current research in the area of neuropharmacological mechanism of antidepressant response and novel strategies used to enhance it.

I would like to thank to the authors of the Issue for their outstanding review manuscripts in their area of expertise, such as augmentation and facilitation of antidepressant treatment by pindolol, thyroid hormone, lithium or neurokenin, catecholaminergic strategies for the treatment of major depression and the role of serotonin-dopamine interaction in the antidepressant response.

Especial acknowledgement should be given to my mentors, Michael E. Newman, Ph.D., Gal Yadid, Ph.D., and Pierre Blier, M.D., Ph.D., for their help and guidance during the Issue preparation, to Bernard Lerer, M.D. for his introduction to the Issue, to the Editor-in-chief, Francis J. Castellino, Ph.D., for his kind invitation, to the reviewers, and to the Issue Manager, Ms. Saima Ghaffar Rao, for coordinating the entire project.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: Issue Editor Departement of Bioinformatics and Biotechnology Jerusalem College of Technology, Israel, and University of Ottawa Institute of Mental Health Research, Ontario, Canada.

Publication date: 2006-02-01

More about this publication?
  • Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more